Table 6.
Anticoagulant Use Phenotypes and Bleeding, Mortality, and Length of Stay, With High Use Defined as in the Top Quartile of Utilization
| Anticoagulant Use Phenotypes | High Bival, High LMWH (n=5) | High Bival, Low LMWH (n=60) | Low Bival, High LMWH (n=59) | Low Bival, Low LMWH (n=133) | P Value |
|---|---|---|---|---|---|
| Observed bleeding rate, % | 3.4 (1.2 to 6.8) | 3.5 (2.3 to 5.0) | 4.1 (3.1 to 5.6) | 3.8 (2.7 to 5.4) | 0.345 |
| RS-bleeding rate, adjusted for patient factors, % | 4.0 (3.9 to 4.4) | 4.2 (3.8 to 4.4) | 4.1 (3.8 to 4.6) | 4.0 (3.8 to 4.5) | 0.827 |
| RS-bleeding rate, also adjusted for anticoagulant, % | 4.1 (3.9 to 4.4) | 4.2 (3.8 to 4.4) | 4.1 (3.8 to 4.7) | 4.0 (3.8 to 4.4) | 0.464 |
| RS-mortality rate, % | 2.3 (2.3 to 2.4) | 2.2 (2.0 to 2.5) | 2.4 (2.1 to 2.6) | 2.2 (2.0 to 2.5) | 0.123 |
| RS-length of stay, days | 2.6 (2.5 to 3.1) | 2.8 (2.6 to 3.1) | 3.2 (2.9 to 3.5) | 3.0 (2.7 to 3.2) | <0.001 |
All values are expressed as median (IQR). High users of bivalirudin and LMWH based on the highest quartile of use in the study cohort (66.5% and 19.7%, respectively). Bival indicates bivalirudin; IQR, interquartile range; LMWH, low-molecular-weight heparin; RS, risk standardized.